

## Article

# Unique Phenanthrenes from *Juncus ensifolius* and Their Antiproliferative and Synergistic Effects with the Conventional Anticancer Agent Doxorubicin against Human Cancer Cell Lines

Dóra Stefkó <sup>1</sup>, Norbert Kúsz <sup>1</sup>, Nikoletta Szemerédi <sup>2</sup>, Anita Barta <sup>1</sup>, Gabriella Spengler <sup>2</sup>, Róbert Berkecz <sup>3</sup>, Judit Hohmann <sup>1,4</sup> and Andrea Vasas <sup>1,\*</sup>

<sup>1</sup> Department of Pharmacognosy, Interdisciplinary Excellence Centre, University of Szeged, 6720 Szeged, Hungary; stefko.dori@gmail.com (D.S.); kusznorbert@gmail.com (N.K.); bartaanita96@gmail.com (A.B.); hohmann.judit@szte.hu (J.H.)

<sup>2</sup> Department of Medical Microbiology, Albert Szent-Györgyi Health Center, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary; szemeredi.nikoletta@med.u-szeged.hu (N.S.); spengler.gabriella@med.u-szeged.hu (G.S.)

<sup>3</sup> Institute of Pharmaceutical Analysis, University of Szeged, 6720 Szeged, Hungary; berkecz.robert@szte.hu

<sup>4</sup> Interdisciplinary Centre of Natural Products, University of Szeged, 6720 Szeged, Hungary

\* Correspondence: vasas.andrea@szte.hu; Tel.: +36-62-546451

**Citation:** Stefkó, D.; Kúsz, N.; Szemerédi, N.; Barta, A.; Spengler, G.; Berkecz, R.; Hohmann, J.; Vasas, A. Unique Phenanthrenes from *Juncus ensifolius* and Their Antiproliferative and Synergistic Effects with the Conventional Anticancer Agent Doxorubicin against Human Cancer Cell Lines. *Pharmaceutics* **2022**, *14*, 608. <https://doi.org/10.3390/pharmaceutics14030608>

Academic Editor: Maria Rosaria Lauro

Received: 11 February 2022

Accepted: 8 March 2022

Published: 10 March 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Phenanthrenes are the main special metabolites of Juncaceae species from phytochemical, pharmacological, and chemotaxonomical points of view. The present study focused on the isolation, structure determination, and pharmacological investigation of phenanthrenes from *Juncus ensifolius*. Nineteen compounds, including 17 phenanthrenes, were identified from the methanol extract of the plant. Thirteen compounds, namely, ensifolins A–M (**1–13**), were obtained for the first time from natural sources. Four phenanthrenes [2-hydroxy-1,7-dimethyl-5-vinyl-9,10-dihydrophenanthrene (**14**), juncuenin B (**15**), juncatrin B (**16**), and sylvaticin A (**17**)], 4-hydroxybenzaldehyde (**18**) and luteolin (**19**) were isolated for the first time from *J. ensifolius*. Ensifolins A (**1**) and B (**2**) are structurally unique phenanthrenes, considering that they are flavonoid- (**1**) or benzaldehyde-adducts (**2**). The antiproliferative activity of all isolated compounds against HeLa, COLO 205, and COLO 320 cancer cells and a non-tumor (MRC-5) cell line was tested using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) viability assay. The luteolin-substituted phenanthrene ensifolin A (**1**) proved to be the most active against all three cancer cell lines (IC<sub>50</sub> values 3.9–12.7 μM) and showed good selectivity (SI = 4.95) in the case of COLO 205. The best selectivity was recorded for ensifolins D (**4**, SI > 5.15, HeLa), H (**8**, SI > 8.13, HeLa), and **17** (SI > 9.43, HeLa). The synergistic activity of the compounds with doxorubicin was also tested on HeLa cells, and ensifolins E (**5**) and H (**8**) exhibited very strong synergism (CI < 0.1). In conclusion, these phenanthrenes are worthy of further investigation.

**Keywords:** *Juncus ensifolius*; Juncaceae; phenanthrene; antiproliferative; doxorubicin; combination assay; synergism

## 1. Introduction

Cancer is one of the leading causes of death globally, and the development of new anticancer agents is the focus of research worldwide. Natural products are still the best options for finding novel agents/active templates and offer the potential to discover novel structures that can lead to effective agents for a variety of human diseases [1]. Novel biomolecules have an advantage in terms of biosafety and they can serve as leads for synthetic chemists and pharmacologists. The effective anticancer drugs often

work by inhibiting angiogenesis, inducing apoptosis, and blocking cancer cells from proliferating. A common feature of phytochemicals is attenuating cancer progression by inhibition of inflammation and induction of apoptosis through caspase-dependent mechanisms or induction of intracellular oxidative stress. Several molecular targets and the action mechanisms of these molecules have already been explored, and great efforts are performed regarding their efficiency by using structure-based drug-design strategies. Ligand-based drug design is used when the target is unknown in order to identify the features of potential receptors. The molecular docking of natural compounds with the receptor targets followed by ADMET (absorption, distribution, metabolism, excretion, toxicity) analysis could help to increase the hit probability of effective drugs [2]. Moreover, natural compounds can target multiple key regulators, e.g., safranal, a metabolite of *Crocus sativus*, in the case where tumor angiogenesis significantly affects the strong interplay of hepatocellular carcinoma cells, endothelial cells, and multiple signaling molecules involved in tumor angiogenesis by downregulation of the in vitro expression of HIF-1 $\alpha$ , VEGF, VEGFR2, p-AKT, p-ERK1/2, MMP9, p-FAK, and p-STAT3 [3]. Ginger and its active ingredients (e.g., gingerols and shogaols) could protect rat liver from cancer via synergistic multi targeted effects including antioxidants and anti-inflammatory by down regulating NF- $\kappa$ B. This effect is related to promoting apoptosis, inhibiting the proliferation of cells, preventing oxidative stress, and reducing COX-2, iNOS, and NF- $\kappa$ B p65 expressions [4].

Conventional chemotherapy plays an important role in the treatment of cancers, but clinical limitations exist because of dose-limiting side effects and drug resistance. Therefore, combination treatment of chemotherapeutic agents and natural compounds is considered to be a promising therapeutic strategy with a higher clinical efficacy. Doxorubicin is routinely used as a single drug for the treatment of patients with different types of cancer. It intercalates into DNA, stabilizes the topoisomerase II protein, and causes cell death via inhibition of topoisomerase II and the generation of reactive oxygen species and free radicals by redox reactions [5]. Although doxorubicin is an effective antineoplastic agent and has cytotoxic effects, resistance limits its use in chemotherapy [6]. A growing body of combination treatments with natural products has been reported to synergistically prevent tumor growth [5]. Besides combination with standard drugs, the efficacy and bioavailability of natural compounds can further increase by applying different formulation techniques. Recent advances in drug delivery systems describe the use of nanoemulsions, nanoparticles, liposomes, and films to carry various phytochemicals such as berberine, curcumin, resveratrol, camptothecins, and celastrol, showing a promising improved anti-cancer action [7,8].

A promising group of natural small molecules are phenanthrenes. The occurrence of these compounds in nature is limited to only a few plant families. Among them, Orchidaceae and Juncaceae are the most abundant sources of these specific metabolites. Phenanthrenes have chemotaxonomical significance since the presence of certain substituents in them are apparently restricted to certain families; e.g., almost all of the stilbene- and *p*-hydroxybenzyl-substituted compounds have been reported in Orchidaceae species, while vinyl substitution occurs only in Juncaceae phenanthrenes [9,10]. Moreover, phenanthrenes possess noteworthy pharmacological activities, such as antiproliferative, anti-inflammatory, and antimicrobial properties [11]. Among Juncaceae phenanthrenes, dehydroeffusol, juncusol, and juncuenin B seem to be the most promising. All of them showed a noteworthy antiproliferative effect against different human cancer cell lines. Dehydroeffusol dose dependently (12–48  $\mu$ M) inhibited gastric cancer cell-mediated vasculogenic mimicry in SGC-7901 cells. It also decreased VE-cadherin expression and exposure, suppressed the MMP2 protease expression and activity, and inhibited gastric cancer cell adhesion, migration, and invasion [12]. Moreover, it inhibited the gastric cell growth and the tumorigenicity by inducing tumor-suppressive ER stress responses [13]. The flow cytometric cell-cycle analysis of juncusol showed that juncusol treatment of HeLa cells for 24 h increased the cell population in the G2/M and sub-G1 phases. It also showed pro-

apoptotic properties through the presence of active caspase-3, 8, and 9 in HeLa cells, suggesting that juncusol causes cell death by apoptosis induction and inhibition of tubulin polymerization in vitro [14]. Juncuenin possessed promising antiproliferative activity ( $IC_{50}$  2.9  $\mu$ M) against HeLa cells. One of its semisynthetic derivatives, differing only in the presence of a methoxy group at C-8a and a carbonyl group at ring C, showed an even higher inhibitory effect ( $IC_{50}$  0.9  $\mu$ M) [15]. In a superoxide anion generation assay, remarkable anti-inflammatory activity was determined for juncusol ( $IC_{50}$  3.1  $\mu$ M) and juncuenin B ( $IC_{50}$  4.9  $\mu$ M). The latter also inhibited elastase release in human neutrophils ( $IC_{50}$  of 5.5  $\mu$ M) in response to fMLP/CB activation [16].

In continuation of our work aiming at the isolation of biologically active compounds from Juncaceae species, *Juncus ensifolius* Wikstr. was investigated. *J. ensifolius* (swordleaf rush) is a ruderal species of rush that occurs from near sea level to subalpine elevations throughout western North America and East Asia [17]. In Europe, Australia, New Zealand, and Hawaii, *J. ensifolius* became naturalized in the 20th century. It is used as an attractive plant in garden ponds [17]. Historically, the plant was used by indigenous people in western North America for weaving mats and baskets and as food, fodder, and medicine [18,19]. The phytochemistry and pharmacology of this plant have not been previously investigated. In this work, we report on the isolation, structure determination, and antiproliferative investigation of phenanthrenes from swordleaf rush, as well as evaluation of its synergistic effects with the conventional anticancer agent doxorubicin.

## 2. Materials and Methods

### 2.1. General Procedures

Optical rotations were measured using a JASCO P-2000 polarimeter (JASCO, Tokyo, Japan). Vacuum liquid chromatography (VLC) was carried out on silica gel (15  $\mu$ m, Merck); a LiChroprep RP-18 (40–63  $\mu$ m, Merck) stationary phase was used for reversed-phase VLC. Medium-pressure liquid chromatography (MPLC) was processed with a Combi Flash Rf+ Lumen instrument (Teledyne Isco) on a reversed-phase RediSep Rf HP Gold (50 g) column. Sephadex LH-20 (25–100  $\mu$ m, Sigma–Aldrich) was used for gel filtration. HPLC was carried out on a Waters HPLC, using a reversed-phase (Phenomenex, Kinetex 5  $\mu$ m C18 100A) column. For the investigation of compounds with chiral carbon atoms, a Lux amylose-1 column (250  $\times$  21.2 mm) (Phenomenex, Torrance, CA, USA) was used with cyclohexane-isopropanol 85:15 as the mobile phase. All solvents used for column chromatography (CC) were of at least analytical grade (VWR Ltd., Debrecen, Hungary).

NMR spectra (Figures S1–S78) were recorded in  $CDCl_3$  and methanol- $d_4$  on a Bruker Avance DRX 500 spectrometer at 500 MHz ( $^1H$ ) and 125 MHz ( $^{13}C$ ). The signals of the deuterated solvents were considered reference points. Chemical shifts ( $\delta$ ) of the reported compounds are given in ppm, and coupling constant values ( $J$ ) are reported in Hz. The high-resolution MS spectra were acquired on a Thermo Scientific Q-Exactive Plus Orbitrap mass spectrometer equipped with an ESI ion source in positive ionization mode. The data were acquired and processed with MassLynx software.

### 2.2. Plant Material

*Juncus ensifolius* Wikstr. was bought from a horticultural company (Mocsáry Évelőkertészet, Tárnok, Hungary) in August 2019. A voucher specimen (No. 890) has been deposited in the Herbarium of Department of Pharmacognosy, University of Szeged, Szeged, Hungary.

### 2.3. Extraction and Isolation

The air-dried whole plant of *J. ensifolius* (1.62 kg) was thoroughly percolated with methanol (MeOH, 50 L) at room temperature. The methanolic extract was concentrated (300 g) under reduced pressure, and solvent–solvent partitioning was applied by using hexane (8 × 0.5 L), chloroform (CHCl<sub>3</sub>, 10 × 0.5 L), and ethyl acetate (EtOAc, 8 × 0.5 L).

The concentrated CHCl<sub>3</sub>-soluble fraction (12 g) was separated by VLC on silica gel using a gradient solvent system of cyclohexane–EtOAc–MeOH [from 98:2:0 to 1:1:1] to collect 14 major fractions (A–N). The result of the fractionation procedure was investigated by a TLC chromatograph, and fractions containing phenanthrenes of similar polarity were combined accordingly. In the second step, all major fractions were further separated by gel chromatography on a Sephadex LH-20 stationary phase using CH<sub>2</sub>Cl<sub>2</sub>–MeOH (1:1) as the eluent. Fractions A/2, F/3, and H/4 were pure and yielded compounds **14** (5.8 mg) from B/2, **15** (51 mg) from F/3, and compound **9** (8.4 mg) from H/4. Fraction B/2 was separated by reversed-phase (RP) HPLC under isocratic conditions, using MeOH–H<sub>2</sub>O (78:22 in 10 min; flow rate 1 mL/min) as the mobile phase, and one compound was obtained **4** (*t<sub>R</sub>* = 6.8 min, 2.5 mg). Purification of fraction D/2 was performed by RP-HPLC under gradient conditions using MeOH–H<sub>2</sub>O (from 8:2 to 93:3 in 10 min, then washed with pure MeOH in 1 min; flow rate 1 mL/min) as the mobile phase to yield compounds **11** (*t<sub>R</sub>* = 8.4 min, 1.8 mg), **2** (*t<sub>R</sub>* = 9.8 min, 3.0 mg), and **10** (*t<sub>R</sub>* = 10.4 min, 1.5 mg). After gel filtration of fraction E on Sephadex LH-20, fraction E/4 was further separated by RP-MPLC by MeOH–H<sub>2</sub>O gradient elution (from 1:9 to 1:0), and then subfraction E/4/3 was purified by RP-HPLC using a MeOH–H<sub>2</sub>O solvent system (from 82:18 to 86:14 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compound **12** (*t<sub>R</sub>* = 10.6 min, 1.1 mg). Fraction E/5 was separated by RP-HPLC under gradient conditions using MeOH–H<sub>2</sub>O (from 75:25 to 81:19 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compounds **18** (*t<sub>R</sub>* = 5.5 min, 100.3 mg) and **5** (*t<sub>R</sub>* = 6.4 min, 13.0 mg). Fraction E/6 was also purified by RP-HPLC using MeOH–H<sub>2</sub>O (from 78:22 to 1:0 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compound **13** (*t<sub>R</sub>* = 7.2 min, 1.0 mg). Fraction F/2 was purified by RP-MPLC using MeOH–H<sub>2</sub>O (from 1:9 to 1:0), and then subfraction F/2/3 was further purified by RP-HPLC under gradient conditions using MeCN–H<sub>2</sub>O (from 1:1 to 7:3 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compounds **3** (*t<sub>R</sub>* = 3.7 min, 7.3 mg) and **17** (*t<sub>R</sub>* = 5.2 min, 8.2 mg). Fraction G/3 was separated by RP-HPLC under gradient conditions using MeCN–H<sub>2</sub>O (from 4:6 to 55:45 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compound **7** (*t<sub>R</sub>* = 5.3 min, 2.1 mg). Fraction G/4 was also separated by RP-HPLC using MeOH–H<sub>2</sub>O (from 4:6 to 65:35 in 10 min; flow rate 1 mL/min) as the mobile phase to yield compound **16** (*t<sub>R</sub>* = 7.75 min, 2.1 mg). Purification of fraction I/3 by RP-HPLC under gradient conditions (MeCN–H<sub>2</sub>O from 1:1 to 8:2 in 10 min; flow rate 1 mL/min) yielded compound **8** (*t<sub>R</sub>* = 2.7 min, 2.5 mg). Fraction L/3 was separated by RP-HPLC under gradient conditions using MeCN–H<sub>2</sub>O (from 35:65 to 7:3 in 12 min; flow rate 1 mL/min) as the mobile phase to yield compounds **6** (*t<sub>R</sub>* = 5.15 min, 4.7 mg) and **1** (*t<sub>R</sub>* = 10.75 min, 2.0 mg). After gel filtration, fraction M was pure and yielded luteolin (4.2 mg) from M/2.

### 2.4. Physical Characteristics of New Compounds

*Ensifolin A* (**1**): light-yellow amorphous solid;  $[\alpha]_D^{25} +9$  (*c* 0.10, MeOH); <sup>1</sup>H and <sup>13</sup>C-NMR data (CD<sub>3</sub>OD, see Table 1); HRESIMS *m/z* 551.1708 [M – H<sub>2</sub>O + H]<sup>+</sup> (calcd for C<sub>33</sub>H<sub>27</sub>O<sub>8</sub>, 551.1706).

**Table 1.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compounds 1–3.

Position	1 <sup>a</sup>		2 <sup>b</sup>		3 <sup>a</sup>	
	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type
1		121.1, C		117.5, C		123.5, C
1a		139.5, C		135.9, C		139.4, C
2		155.0, C		152.4, C		155.9, C
3	6.66, d (8.6)	112.8, CH	6.86, d (8.6)	114.1, CH	6.76, d (8.4)	114.3, CH
4	7.97, d (8.6)	128.1, CH	7.53, d (8.6)	129.3, CH	7.38, d (8.4)	129.2, CH
4a		125.8, C		127.6, C		126.4, C
5a		123.2, C		130.6, C		132.0, C
5		155.3, C		135.3, C		136.0, C
6	6.67, s	118.5, CH	7.25, br s	127.7, CH	7.21, br s	128.5, CH
7		136.8, C		136.3, C		136.8, C
8		122.1, C	7.02, br s	127.9, CH	7.03, br s	130.5, CH
8a		140.9, C		138.5, C		134.8, C
9	2.77, m 2.87, m	27.8, CH <sub>2</sub>	2.73, m (2H)	29.6, CH <sub>2</sub>	2.84, dd (16.0, 3.0) 3.05, dd (16.0, 2.8)	39.1, CH <sub>2</sub>
10	2.64, m (2H)	26.5, CH <sub>2</sub>	2.54, m (2H)	24.1, CH <sub>2</sub>	5.10, br t (2.8)	64.3, CH
11	2.18, s (3H)	11.6, CH <sub>3</sub>	5.09, d (14.5) 5.19, d (14.5)	66.2, CH <sub>2</sub>	2.33*, s (3H)	11.1, CH <sub>3</sub>
OCH <sub>3</sub> –11						
12	2.38, s (3H)	20.7, CH <sub>3</sub>	6.98, dd (17.4, 10.9) 5.28, dd (10.9, 1.3)	138.9, CH	7.02, dd (17.4, 10.9) 5.21, dd (10.9, 1.4)	140.9, CH
13	5.65, dd (9.9, 2.9)	75.6, CH	5.72, dd (17.4, 1.3)	114.7, CH <sub>2</sub>	5.66, dd (17.4, 1.4)	113.6, CH <sub>2</sub>
14	4.32, dd (11.9, 2.9) 4.42, dd (11.9, 9.9)	67.1, CH <sub>2</sub>	2.37, s (3H)	21.2, CH <sub>3</sub>	2.33 *, s (3H)	21.1, CH <sub>3</sub>

<sup>a</sup> measured in methanol-*d*<sub>4</sub>; <sup>b</sup> measured in CDCl<sub>3</sub>; \* overlapping signals; luteolin part of compound 1:  $\delta_{\text{H}}$  – 6.63 (H-3'; 1H, s), 6.23 (H-6'; 1H, d,  $J = 2.1$  Hz), 6.47 (H-8'; 1H, d,  $J = 2.1$  Hz), 7.57 (H-2''; 1H, d,  $J = 2.2$  Hz), 7.06 (H-5''; 1H, d,  $J = 8.6$  Hz), 7.53 (H-6''; 1H, dd,  $J = 8.6$  and 2.2 Hz);  $\delta_{\text{C}}$  (with types of carbons) – 165.5 (C-2'; C), 104.9 (C-3'; CH), 183.9 (C-4'; C), 105.5 (C-4a'; C), 163.3 (C-5'; C), 100.3 (C-6'; CH), 166.3 (C-7'; C), 95.2 (C-8'; CH), 159.5 (C-8a'; C), 125.6 (C-1''; C), 116.6 (C-2''; CH), 145.0 (C-3''; C), 148.6 (C-4''; C), 119.2 (C-5''; CH), 121.3 (C-6''; CH); hemiacetal part originated from 4-hydroxybenzaldehyde of compound 2:  $\delta_{\text{H}}$  – 5.94 (H-1'; 1H, s), 7.50 (H-3'/H-7'; 2H, d,  $J = 8.5$  Hz), 6.89 (H-4'/H-6'; 2H, d,  $J = 8.5$  Hz);  $\delta_{\text{C}}$  (with types of carbons) – 98.7 (C-1'; CH), 129.8 (C-2'; C), 2 × 128.2 (C-3'/C-7'; 2 × CH), 2 × 115.5 (C-4'/C-6'; 2 × CH), 156.7 (C-5'; C).

*Ensifolin B (2)*: light-yellow amorphous solid;  $[\alpha]_{\text{D}}^{25} +2$  (c 0.10, MeOH); <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 1; HRESIMS  $m/z$  369.1497 [M – H<sub>2</sub>O – H]<sup>–</sup> (calcd for C<sub>25</sub>H<sub>21</sub>O<sub>3</sub>, 369.1491).

*Ensifolin C (3)*: white amorphous solid;  $[\alpha]_{\text{D}}^{25} +2$  (c 0.20, MeOH); <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 1; HRESIMS  $m/z$  265.1265 [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>O<sub>2</sub>, calcd for 265.1234).

*Ensifolin D (4)*: light-yellow amorphous powder; <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 1; HRESIMS  $m/z$  281.1540 [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>21</sub>O<sub>2</sub>, calcd for 281.1536).

*Ensifolin E (5)*: yellow amorphous solid; <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 2; HRESIMS  $m/z$  267.1379 [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>O<sub>2</sub>, calcd for 267.1380).

**Table 2.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compounds 4–6 (in methanol-*d*<sub>4</sub>).

Position	4		5		6	
	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type
1		121.9, C		121.2, C		121.2, C
1a		142.8, C		139.5, C		139.7, C
2		156.5, C		154.7, C		154.9, C
3	6.71, d (8.5)	113.0, CH	6.65, d (8.6)	112.7, CH	6.65, d (8.6)	112.7, CH
4	7.40, d (8.5)	131.6, CH	7.98, d (8.6)	127.9, CH	8.03, d (8.6)	128.1, CH
4a		127.2, C		126.5, C		126.2, C
5a		132.4, C		121.7, C		123.0, C
5		135.9, C		153.8, C		154.2, C
6	7.22, br s	128.0, CH	6.61, s	117.0, CH	6.91, s	114.9, CH
7		136.8, C		135.6, C		138.54 <sup>#</sup> , C
8	7.00, br s	128.5, CH		129.4, C		128.5, C
8a		140.0, C		138.4, C		138.57 <sup>#</sup> , C
9	2.66, m (2H)	31.0, CH <sub>2</sub>	2.72, m (2H)	28.5, CH <sub>2</sub>	2.74, m (2H)	28.2, CH <sub>2</sub>
10	2.77, m (2H)	26.5, CH <sub>2</sub>	2.60, m (2H)	26.7, CH <sub>2</sub>	2.63, m (2H)	26.6, CH <sub>2</sub>
11	4.66, s (2H)	66.5, CH <sub>2</sub>	2.18, s (3H)	11.7, CH <sub>3</sub>	2.19, s (3H)	11.7, CH <sub>3</sub>
OCH <sub>3</sub> –11	3.40, s (3H)	58.1, CH <sub>3</sub>				
12	6.92, dd (17.5, 10.9)	140.3, CH	2.22, s (3H)	20.8, CH <sub>3</sub>	4.58, s (2H)	63.3, CH <sub>2</sub>
13	5.21, dd (10.9, 1.6) 5.68, dd (17.5, 1.6)	113.8, CH <sub>2</sub>	6.72, dd (17.9, 11.3)	136.5, CH	6.79, dd (17.8, 11.3)	135.5, CH
14	2.33, s (3H)	21.1, CH <sub>3</sub>	5.09, dd (17.9, 2.3) 5.48, dd (11.3, 2.3)	119.5, CH <sub>2</sub>	5.17, dd (17.8, 2.2) 5.51, dd (11.3, 2.2)	120.1, CH <sub>2</sub>

<sup>#</sup> interchangeable signals.

*Ensifolin F* (6): light-yellow amorphous powder; <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 2; HRESIMS *m/z* 281.1214 [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>O<sub>3</sub>, calcd for 281.1183).

*Ensifolin G* (7): light-yellow amorphous granules; <sup>1</sup>H and <sup>13</sup>C-NMR data, see Table 3; HRESIMS *m/z* 281.1213 [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>O<sub>3</sub>, calcd for 281.1183).

**Table 3.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compounds 7–9.

Position	7 <sup>a</sup>		8 <sup>a</sup>		9 <sup>b</sup>	
	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type
1		121.5, C		122.7, C		121.5, C
1a		139.1, C		138.7, C		139.1, C
2		155.1, C		156.5, C		155.1, C
3	6.66, d (8.6)	112.9, CH	6.72, d (8.4)	114.1, CH	6.66, d (8.6)	112.9, CH
4	8.03, d (8.6)	128.1, CH	7.38, d (8.4)	123.2, CH	8.03, d (8.6)	128.1, CH
4a		125.5, C		127.0, C		125.5, C
5a		121.8, C		137.5, C		121.8, C
5		155.5, C	7.16, s	112.2, CH		155.5, C
6	6.61, s	117.4, CH		156.1, C	6.61, s	117.4, CH
7		132.4, C		127.2, C		132.4, C
8		134.3, C		122.2, C		134.3, C
8a		135.8, C		131.3, C		135.8, C
9	2.55, m (2H)	28.3, CH <sub>2</sub>	2.94, m (2H)	27.2, CH <sub>2</sub>	2.55, m (2H)	28.3, CH <sub>2</sub>
10	2.68, m (2H)	26.3, CH <sub>2</sub>	2.76, m (2H)	26.1, CH <sub>2</sub>	2.68, m (2H)	26.3, CH <sub>2</sub>
11	2.18, s (3H)	11.7, CH <sub>3</sub>	2.19, s (3H)	11.5, CH <sub>3</sub>	2.18, s (3H)	11.7, CH <sub>3</sub>
12	2.17, s (3H)	19.1, CH <sub>3</sub>	4.93, s (2H)	60.1, CH <sub>2</sub>	2.17, s (3H)	19.1, CH <sub>3</sub>
13		211.4, C		81.1, C		211.4, C
14	2.46, s (3H)	33.1, CH <sub>3</sub>	3.85, s	86.4, CH	2.46, s (3H)	33.1, CH <sub>3</sub>

<sup>a</sup> measured in methanol-*d*<sub>4</sub>; <sup>b</sup> measured in CDCl<sub>3</sub>.

*Ensifolin H (8)*: yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 3; HRESIMS  $m/z$  281.1174  $[\text{M} + \text{H}]^+$  ( $\text{C}_{18}\text{H}_{17}\text{O}_3$ , calcd for 281.1172).

*Ensifolin I (9)*: yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 3; HRESIMS  $m/z$  263.1069  $[\text{M} + \text{H}]^+$  ( $\text{C}_{18}\text{H}_{15}\text{O}_2$ , calcd for 263.1067).

*Ensifolin J (10)*: light-yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 4; HRESIMS  $m/z$  531.2516  $[\text{M} + \text{H}]^+$  ( $\text{C}_{36}\text{H}_{34}\text{O}_4$ , calcd for 531.2530).

**Table 4.**  $^1\text{H}$  (500 MHz) and  $^{13}\text{C}$  (125 MHz) NMR data of symmetric dimers **10** and **13** in methanol- $d_4$ .

Position	10		13	
	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , Type
1, 1'		122.9, C		124.5, C
1a, 1a'		139.0, C		137.7, C
2, 2'		151.4, C		153.3 <sup>+</sup> , C
3, 3'		124.9, C		126.8, C
4, 4'	8.12, s	130.3, CH	7.48, s	125.3, CH
4a, 4a'		127.4, C		128.3 <sup>+</sup> , C
5a, 5a'		121.5, C		134.9, C
5, 5'		153.9, C	7.17, s	111.3, CH
6, 6'	6.60, s	117.0, CH		155.0, C
7, 7'		136.0, C		126.4, C
8, 8'		129.5, C		123.0, C
8a, 8a'		138.6, C		131.2, C
9, 9'	2.82, m (2H)	28.5, CH <sub>2</sub>	2.99, m (2H)	27.5, CH <sub>2</sub>
10, 10'	2.70, m (2H)	26.9, CH <sub>2</sub>	2.84, m (2H)	26.4, CH <sub>2</sub>
11, 11'	2.32, s (3H)	12.4, CH <sub>3</sub>	2.32, s (3H)	12.3, CH <sub>3</sub>
12, 12'	2.23, s (3H)	20.8, CH <sub>3</sub>	2.33, s (3H)	14.1, CH <sub>3</sub>
13, 13'	6.76, dd (17.9, 11.3)	136.5, CH		82.2, C
14, 14'	5.13, dd (17.9, 2.2)	119.6, CH <sub>2</sub>	3.85, s	86.1, C
	5.52, dd (11.3, 2.2)			

<sup>+</sup> only seen in the HMBC spectrum.

*Ensifolin K (11)*: light-yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 5; HRESIMS  $m/z$  529.2366  $[\text{M} + \text{H}]^+$  ( $\text{C}_{36}\text{H}_{33}\text{O}_4$ , calcd for 529.2373).

*Ensifolin L (12)*: light-yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 5; HRESIMS  $m/z$  529.2437  $[\text{M} + \text{H}]^+$  ( $\text{C}_{36}\text{H}_{35}\text{O}_4$ , calcd for 529.2384).

**Table 5.**  $^1\text{H}$  (500 MHz) and  $^{13}\text{C}$  (125 MHz) NMR data of compounds **11** and **12** in methanol- $d_4$ .

Position	11		12	
	$\delta\text{H}$ (J in Hz)	$\delta\text{C}$ , Type	$\delta\text{H}$ (J in Hz)	$\delta\text{C}$ , Type
1		117.4, C		121.2, C
1a		134.9, C		139.82 #, C
2		153.47 #, C		154.9, C
3	6.53, d (9.4)	115.4, CH	6.64, d (8.6)	112.7, CH
4	7.56, d (9.4)	127.1, CH	8.02, d (8.6)	128.2, CH
4a		125.82, C		126.5, C
5a		131.0, C		122.1, C
5		118.6, C		151.3, C
6		153.37 #, C		125.3, C
7		123.3, C		135.4, C
8		138.8, C		130.49, C
8a		125.5, C		137.9, C
9	8.04, d (9.5)	125.80, CH	2.87, m (2H)	28.4, CH <sub>2</sub>
10	7.72, d (9.5)	120.9, CH	2.69 *, m (2H)	26.8, CH <sub>2</sub>
11	2.47, s (3H)	11.2, CH <sub>3</sub>	2.21, s (3H)	11.7, CH <sub>3</sub>
12	2.44, s (3H)	14.5, CH <sub>3</sub>	2.03, s (3H)	18.5, CH <sub>3</sub>
13	7.19, dd (17.9, 11.4)	136.9, CH	6.82, dd (17.8, 11.2)	137.3, CH
14	5.41, dd (17.9, 2.2) 5.85, dd (11.4, 2.2)	121.8, CH <sub>2</sub>	5.16, dd (17.8, 2.4) 5.54, dd (11.2, 2.4)	119.9, CH <sub>2</sub>
1'		123.4, C		122.7, C
1a'		140.5, C		139.89 #, C
2'		152.2, C		152.6, C
3'		123.6, C		120.8, C
4'	7.96, s	130.0, CH	7.92, s	130.38, CH
4a'		128.6, C		127.3, C
5a'		121.2, C		121.4, C
5'		153.9, C		153.9, C
6'	6.55, s	117.0, CH	6.61, s	117.1, CH
7'		136.2, C		136.0, C
8'		129.4, C		129.5, C
8a'		138.4, C		138.5, C
9'	2.77, m 3.05, ddd (15.1, 6.9, 4.3)	28.6, CH <sub>2</sub>	2.78 *, m (2H)	28.8, CH <sub>2</sub>
10'	2.67, m 2.94, ddd (11.1, 6.9, 4.3)	27.1, CH <sub>2</sub>	2.67 *, m 2.77 *, m	27.0, CH <sub>2</sub>
11'	2.32, s (3H)	12.4, CH <sub>3</sub>	2.30, s (3H)	12.3, CH <sub>3</sub>
12'	2.22, s (3H)	20.8, CH <sub>3</sub>	2.23, s (3H)	20.8, CH <sub>3</sub>
13'	6.78, dd (17.9, 11.3)	136.4, CH	6.76, dd (17.8, 11.3)	136.4, CH
14'	5.16, dd (17.9, 2.2) 5.54, dd (11.3, 2.2)	119.7, CH <sub>2</sub>	5.13, dd (17.8, 2.2) 5.52, dd (11.3, 2.2)	119.6, CH <sub>2</sub>

\* overlapping signals; # interchangeable signals reflects the chemical diversity of phenanthrenes.

Ensifolin M (**13**): light-yellow amorphous powder;  $^1\text{H}$  and  $^{13}\text{C}$ -NMR data, see Table 4; HRESIMS  $m/z$  525.2118  $[\text{M} + \text{H}]^+$  ( $\text{C}_{36}\text{H}_{30}\text{O}_4$ , calcd for 525.2071).



## 2.5. Antiproliferative Assays

### 2.5.1. Cell Lines

The human colon adenocarcinoma cells (COLO 205 sensitive and the resistant COLO 320/MDR-LRP expressing P-gp), namely, ATCC-CCL-220.1 (COLO 320) and CCL-222 (COLO 205) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM Na pyruvate, and 100 mM HEPES. HeLa (ATCC® CCL-2™) human cervix carcinoma cells, and MRC-5 (ATCC® CCL-171) human embryonal lung fibroblast cells were cultured in Eagle's minimal essential medium (EMEM, containing 4.5 g/L glucose) supplemented with a non-essential amino acid mixture, a selection of vitamins, and 10% heat-inactivated fetal bovine serum. The cell lines were detached with 0.25% trypsin and 0.02% EDTA for 5 min at 37 °C. All cell lines were purchased from LGC Promochem, Teddington, England.

### 2.5.2. Antiproliferative Assay

In the study, human colonic adenocarcinoma cell lines (doxorubicin-sensitive COLO 205 and multidrug resistant COLO 320 colonic adenocarcinoma cells), HeLa human cervix carcinoma cells and the MRC-5 non-cancerous human embryonic lung fibroblast cell line were used to determine the effect of the compounds on cell growth. The effects of increasing concentrations of compounds on cell growth were tested in 96-well flat-bottomed microtiter plates. The stock solutions of the compounds were prepared in DMSO, and in the final samples, the DMSO content was always lower than 1%. The compounds were diluted in a volume of 100 µL of the medium. The adherent cells were cultured in 96-well flat-bottomed microtiter plates using EMEM supplemented with 10% heat-inactivated fetal bovine serum. The density of the cells was adjusted to  $6 \times 10^3$  cells in 100 µL per well, the cells were seeded prior to the assay for 24 h at 37 °C, with 5% CO<sub>2</sub>, and then the medium was removed from the plates, and fresh medium (100 µL per well) was added to the cells. The effects of increasing concentrations of compounds on cell proliferation were tested in 96-well flat-bottomed microtiter plates. The compounds were diluted in the appropriate medium; the dilutions of compounds were performed in separate plates and then added to the cells. The starting concentration of the compounds was 100 µM, and two-fold serial dilution was performed (concentration range: 100–0.19 µM). The culture plates were incubated at 37 °C for 72 h; at the end of the incubation period, 20 µL of MTT (thiazolyl blue tetrazolium bromide, Sigma) solution (from a stock solution of 5 mg/mL) was added to each well. After incubation at 37 °C for 4 h, 100 µL of sodium dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M HCl) was added to each well, and the plates were further incubated at 37 °C overnight. Cell growth was determined by measuring the optical density (OD) at 540/630 nm, with a Multiscan EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA). Inhibition of cell growth (expressed as IC<sub>50</sub>: inhibitory concentration that reduces the growth of the cells exposed to the tested compounds by 50%) was determined from the sigmoid curve where  $100 - ((OD_{\text{sample}} - OD_{\text{medium control}})/(OD_{\text{cell control}} - OD_{\text{medium control}})) \times 100$  was plotted against the logarithm of the compound concentrations. Curves were fitted by Prism5 software (GraphPad Software Inc., San Diego, CA, USA) from four parallel experiments for each cell line. Results are expressed in terms of IC<sub>50</sub>, defined as the inhibitory dose that reduces the proliferation of the cells exposed to the tested compounds by 50% [20].


### 2.5.3. Drug Combination Assay


The HeLa cell line was used to perform this assay. Doxorubicin (2 mg/mL, Teva Pharmaceuticals, Budapest, Hungary) was serially diluted in the horizontal direction, starting with 8.6 µM. The resistance modifier was subsequently diluted in the vertical direction, and the starting concentration was determined based on the IC<sub>50</sub>. The dilutions of doxorubicin were made in a horizontal direction in 100 µL, and the dilutions of the resistance modifiers occurred vertically in the microtiter plate in a 50 µL volume. The compounds

and doxorubicin were diluted separately. The density of the cells was  $6 \times 10^3$  cells in 100  $\mu\text{L}$  per well, the cells were seeded prior to the assay for 24 h at 37 °C with 5%  $\text{CO}_2$ , and then the medium was removed from the plates, and fresh medium, 50  $\mu\text{L}$  per well, was added to the cells. Then, diluted compounds with a volume of 50  $\mu\text{L}$  were added to each well to reach a final volume of 200  $\mu\text{L}$ . The plates were incubated for 72 h at 37 °C in a  $\text{CO}_2$  incubator, and at the end of the incubation period, the cell growth was determined by the MTT staining method, as described earlier. Drug interactions were evaluated using CompuSyn software [21]. Each dose-response curve (for individual agents as well as combinations) was fit to a linear model using the median effect equation in order to obtain the median effect value (corresponding to the  $\text{IC}_{50}$ ) and slope ( $m$ ) [22,23]. The goodness-of-fit was assessed using the linear correlation coefficient,  $r$ , and only data from analysis with  $r > 0.90$  are presented. The extent of the interaction between drugs was expressed using the combination index in which a CI value close to 1 indicates additivity, while  $\text{CI} < 1$  is defined as synergy and  $\text{CI} > 1$  as antagonism.

### 3. Results and Discussion

The dried whole-plant material (1.62 kg) was extracted with MeOH at room temperature. After evaporation, the extract was dissolved in 50% aqueous MeOH, and solvent-solvent partition was performed with hexane,  $\text{CHCl}_3$ , and EtOAc. The  $\text{CHCl}_3$  phase was separated by a combination of different chromatographic methods, including VLC, MPLC, gel filtration, and HPLC to yield 19 compounds (Figure 1). The structure elucidation was carried out by extensive spectroscopic analysis, using NMR and HRESIMS measurements, and comparison of the spectral data with literature values.





**Figure 1.** Structures of new compounds (1–13) isolated from *J. ensifolius*.


### 3.1. Structure Elucidation of the Isolated Compounds

#### 3.1.1. Ensifolin A (1)

Compound **1** was isolated as light-yellow amorphous solid. Its HRESIMS peak at  $m/z$  551.1708  $[M - H_2O + H]^+$  (calcd for 551.1706) suggested a molecular formula  $C_{33}H_{27}O_8$ . The  $^1H$  NMR spectrum (Table 1) exhibited resonances of an *ortho*- ( $\delta_H$  7.97 and 6.66, each 1H, d,  $J = 8.6$  Hz) and a *meta*-coupled ( $\delta_H$  6.47 and 6.23, each 1H, d,  $J = 2.1$  Hz) pair of aromatic protons, the signals of a 1,3,4-trisubstituted aromatic ring ( $\delta_H$  7.57, 1H, d,  $J = 2.2$  Hz;  $\delta_H$  7.53, 1H, dd,  $J = 8.6$  and 2.2 Hz;  $\delta_H$  7.06, 1H, d,  $J = 8.6$  Hz), two aromatic singlets ( $\delta_H$  6.67 and 6.63), two methylenes ( $\delta_H$  2.87 and 2.77, each 1H, m;  $\delta_H$  2.64, 2H, m), two methyls ( $\delta_H$  2.38 and 2.18, each 3H, s), and a mutually coupled oxymethine ( $\delta_H$  5.65, 1H, dd,  $J = 9.9$  and 2.9 Hz) and oxymethylene group ( $\delta_H$  4.42, 1H, dd,  $J = 11.9$  and 9.9 Hz;  $\delta_H$  4.32, 1H, dd,  $J = 11.9$  and 2.9 Hz). The 33 carbon resonances detected in the  $^{13}C$  JMOD NMR spectrum were categorized based on their HSQC correlations and chemical shifts. A keto group at  $\delta_C$  183.9, the aforementioned *meta*-coupled aromatic methines ( $\delta_H$  6.47 d and 6.23 d, ring A) and a lone proton singlet ( $\delta_H$  6.63, ring C) attached to upfield shifted  $sp^2$  carbons ( $\delta_C$  95.2, 100.3, and 104.9, respectively), as well as the presence of a 1,3,4-trisubstituted benzene ring (C-1''–C-6'', ring B) suggested that compound **1** contains a 5,7,3',4'-tetrahydroxyflavone structural portion. The polyphenol was readily identified as luteolin, a common tetrahydroxyflavone previously described from various *Juncus* species [24,25]. Its  $^1H$  and  $^{13}C$  carbon assignments were in strong agreement with literature values with the exception of small differences observed for ring B, implying that luteolin is connected to the other part of the molecule through its OH-3' or OH-4' group [26].

The remaining 18 carbons, including two saturated methylenes at  $\delta_C$  27.8 and 26.5 were reminiscent of a 9,10-dihydrophenanthrene derivative. The  $^1H$ - $^1H$  COSY spectrum defined four sequences of correlated protons, namely, a  $-CH=CH-$  ( $\delta_H$  6.66 d and 7.97 d; H-3/H-4), a  $-CH_2-CH_2-$  ( $\delta_H$  2.87 m (1H), 2.77 m (1H), and 2.64 m (2H); H<sub>2</sub>-9/H<sub>2</sub>-10), and a  $-CH(OR)-CH_2(OR)-$  ( $\delta_H$  5.65 dd, 4.42 dd, and 4.32 dd; H-13/H<sub>2</sub>-14) fragment (Figure 2). The HMBC correlations from H-4, H<sub>2</sub>-9, H<sub>2</sub>-10, and H<sub>3</sub>-11 to C-1a ( $\delta_C$  139.5), from H-3 and H<sub>2</sub>-10 to C-4a ( $\delta_C$  125.8), and from H-4, H-6, and H<sub>2</sub>-9 to C-5a ( $\delta_C$  123.2) established the

phenanthrene skeleton (Figure 2). According to the long-range heteronuclear correlations between H<sub>3</sub>-11 and C-1a, C-1 ( $\delta_c$  121.1), C-2 ( $\delta_c$  155.0), and between H-4 and C-2, a methyl and a hydroxy group was placed onto C-1 and C-2, respectively. In a similar manner, HMBC interactions of H-6 with C-5 ( $\delta_c$  155.3) and of H<sub>3</sub>-12 ( $\delta_H$  2.38) with C-6 ( $\delta_c$  118.5), C-7 ( $\delta_c$  136.8), and C-8 ( $\delta_c$  122.1) revealed the presence of a further hydroxy on C-5 and a methyl group on C-7. Additional HMBC correlations H-13/C-7, H-13/C-8, H-13/C-8a ( $\delta_c$  140.9), H-6/C-8, and H<sub>2</sub>-9/C-8 dictated that the H-13–H<sub>2</sub>-14 [–CH(OH)–CH<sub>2</sub>(OR)–] moiety is situated on C-8. The side chain presumably originated from a vinyl group, which is characteristic of many phenanthrenes isolated from Juncaceae plants. The structure of this new phenanthrene found in compound **1** was determined as 2,5-dihydroxy-8-(1-hydroxyethyl)-1,7-dimethyl-9,10-dihydrophenanthrene. The NOE cross peaks H<sub>3</sub>-11/H<sub>2</sub>-10, H<sub>3</sub>-12/H-6, H<sub>3</sub>-12/H-13, and H-13/H<sub>2</sub>-9 were consistent with the proposed structure, as depicted in Figure 2. Furthermore, a three-bond HMBC correlation between H<sub>2</sub>-14b ( $\delta_H$  4.32) and C-3" ( $\delta_c$  145.0) demonstrated that the phenanthrene and luteolin units are linked together by an ether bond formed between C-14 and C-3".



**Figure 2.** Key <sup>1</sup>H–<sup>1</sup>H COSY (–) and HMBC (H→C) correlations of ensifolin A (**1**).

Compound **1** has an asymmetric carbon atom (C-14). The specific rotation value  $[\alpha]_D^{25}$  of the compound was +9 (*c* 0.1, MeOH). When ensifolin A (**1**) was injected onto a chiral HPLC column, it eluted with two well-separated peaks with a peak ratio area of 1:1. The peaks exhibited the same UV spectra, suggesting that **1** is a racemic mixture, with the structure shown in Figure 2. To the best of our knowledge, this is the first time that a naturally occurring phenanthrene-flavonoid conjugate is reported from the plant kingdom.

### 3.1.2. Ensifolin B (**2**)

Compound **2** (ensifolin B) has the molecular formula C<sub>25</sub>H<sub>24</sub>O<sub>4</sub> compatible with the fragment ion in the HRESIMS at *m/z* 369.1497 [M – H<sub>2</sub>O – H]<sup>+</sup> (calcd for 369.1491). The <sup>1</sup>H NMR spectrum displayed the typical signals of a vinyl-substituted 9,10-dihydrophenanthrene, together with resonances of an isolated oxymethylene ( $\delta_H$  5.19 and 5.09, each 1H, d, *J* = 14.5 Hz;  $\delta_c$  66.2), a hemiacetal group ( $\delta_H$  5.94, 1H, s;  $\delta_c$  98.7), and a *para*-disubstituted benzene ring ( $\delta_H$  7.50 and 6.89, each 2H, d, *J* = 8.5 Hz). The structure of the phenanthrene skeleton was assembled through 2D NMR analysis. It was concluded that the phenanthrene core of compound **2** is identical to sylvaticin A, a 9,10-dihydrophenanthrene recently described from *Luzula sylvatica* [27]. However, NMR characteristics of the H<sub>2</sub>-11 oxymethylene in **2** are different compared to those of sylvaticin A, including its upfield shifted carbon ( $\delta_c$  66.2 vs. 60.2) and magnetically inequivalent protons ( $\delta_H$  5.19 and 5.09, vs.  $\delta_H$  5.01, 2H, s). These findings, in conjunction with HMBC interactions from H<sub>2</sub>-11 to the deshielded hemiacetal carbon ( $\delta_c$  98.7), from H-7' ( $\delta_H$  5.94) to C-3'/C-7' ( $\delta_c$  128.2) and from H-3'/H-7' ( $\delta_H$  7.50) to C-5' ( $\delta_c$  156.7), unequivocally demonstrated that OH-11 and a 4-hydroxybenzaldehyde unit participated in the formation of an acyclic hemiacetal moiety. Similar to compound **1**, ensifolin B (**2**) also has an asymmetric carbon atom (C-1'). The specific rotation value  $[\alpha]_D^{25}$  of the compound was +2 (*c* 0.1, MeOH). When compound **2** was injected onto a chiral HPLC column, it eluted with two well-separated peaks with a peak ratio area of 1:1. The peaks exhibited the same UV spectra, suggesting that **2** is a racemic mixture. Intermolecular hemiacetals are intrinsically unstable with respect to their parent alcohols and aldehydes. Indeed, the initially pure phenanthrene showed signs

of decomposition, as two sets of proton signals (in an approximate 1:0.6 ratio) emerged in the  $^1\text{H}$  NMR spectrum when measured again one day later. Considering that sylvaticin A and 4-hydroxybenzaldehyde, the minor compounds of the mixture were also isolated from other fractions (compound **16** and **18**, respectively), it is unclear whether these phytochemicals originally presented in the harvested plant material or whether they are just by-products of the decomposition of compound **2**.

### 3.1.3. Ensifolin C (3)

Compound **3** was obtained as a white, amorphous solid. The HRESIMS peak of the protonated molecule at  $m/z$  265.1265  $[\text{M} + \text{H}]^+$  ( $\text{C}_{18}\text{H}_{19}\text{O}_2$ , calcd for 265.1234) established a molecular formula  $\text{C}_{18}\text{H}_{18}\text{O}_2$ . Analysis of the NMR spectra yielded a 9,10-dihydrophenanthrene skeleton containing a rare 10-OH group ( $\delta_{\text{H}10}$  5.10, 1H, br t,  $J = 2.9$  Hz;  $\delta_{\text{C}10}$  64.3). Comparison with literature data showed that ensifolin C is the 2-demethyl derivative of sylvaticin B, which was isolated from *L. sylvatica* [27]. The structure of compound **3** was therefore determined to be 2,10-dihydroxy-1,7-dimethyl-5-vinyl-9,10-dihydrophenanthrene. Investigation of the compound on a chiral HPLC column resulted in only one peak. According to literature data on similar 10-hydroxyphenanthrenes, the configuration of C-10 can be assumed as (*S*) [27,28].

### 3.1.4. Ensifolin D (4)

Compound **4** was isolated as a light-yellow amorphous powder, and the formula  $\text{C}_{19}\text{H}_{20}\text{O}_2$  was assigned to it based on its protonated molecular peak at  $m/z$  281.1540  $[\text{M} + \text{H}]^+$  (calcd for 281.1536) in the HRESIMS. The 1D NMR spectra implied that the chemical structure of compound **4** is very similar to that of sylvaticin A. The upfield shifted C-11 ( $\delta_{\text{C}}$  66.5 vs. 56.7 in methanol- $d_4$ ), as well as a diagnostic HMBC interaction between a methoxy function ( $\delta_{\text{H}}$  3.40, 3H, s;  $\delta_{\text{C}}$  66.5) and H<sub>2</sub>-11 ( $\delta_{\text{H}}$  4.66, 2H, s) dictated that ensifolin D is the 11-methoxy derivative of sylvaticin A.

### 3.1.5. Ensifolin E (5)

Compound **5** has the molecular formula  $\text{C}_{18}\text{H}_{18}\text{O}_2$  according to its protonated molecular peak at  $m/z$  267.1379  $[\text{M} + \text{H}]^+$  in the HRESIMS (calcd for 267.1380). The  $^1\text{H}$  and  $^{13}\text{C}$  JMOD NMR spectra displayed the characteristic signals of a 9,10-dihydrophenanthrene scaffold ( $\delta_{\text{H}}$  2.60 and 2.72, each 2H, m;  $\delta_{\text{C}}$  26.7 and 28.5) substituted with two methyls, a vinyl side-chain, and two hydroxy groups ( $\delta_{\text{C}}$  153.8 and 154.7). Apart from these resonances, a lone aromatic singlet ( $\delta_{\text{H}}$  6.61, 1H) and two *ortho*-coupled aromatic protons ( $\delta_{\text{H}}$  6.65 and 7.98, each 1H, d,  $J = 8.6$  Hz) were also detected in the  $^1\text{H}$  NMR data. The HMBC interactions of H<sub>3</sub>-11 with C-1, C-1a and C-2 and of H-4 with C-1a and C-2 assembled ring A. Correlations of the saturated methylenes H<sub>2</sub>-9 and H<sub>2</sub>-10 with C-1, C-1a, and C-4a connected rings A and B. The second methyl and the vinyl group are attached to the core at C-7 and C-8, respectively, as demonstrated by the H<sub>3</sub>-12/C-6, H<sub>3</sub>-12/C-7, H<sub>3</sub>-12/C-8, H-13/C-8a, H-14/C-8, and H<sub>2</sub>-9/C-8 heteronuclear long-range correlations. Further two- and three-bond HMBC interactions of H-6 ( $\delta_{\text{H}}$  6.61) with C-5a, C-5 ( $\delta_{\text{C}}$  154.7), and C-8 allowed the placement of an -OH group onto C-5 and established the final structure of **5** as 2,5-dihydroxy-1,7-dimethyl-8-vinyl-9,10-dihydrophenanthrene. The NOE cross-peaks H<sub>2</sub>-10/H<sub>3</sub>-11, H-6/H<sub>3</sub>-12, H-13/H<sub>3</sub>-12, H-13/H<sub>2</sub>-9, and H-14b/H<sub>2</sub>-9 corroborated with the proposed structure of ensifolin E.

### 3.1.6. Ensifolin F (6)

The isolation process yielded compound **6** (ensifolin F) as a light-yellow amorphous powder. The molecular formula  $\text{C}_{18}\text{H}_{18}\text{O}_3$  of **6** was deduced from the HRESIMS peak at  $m/z$  281.1214  $[\text{M} + \text{H}]^+$  (calcd for 281.1183). The 1D NMR data suggested that compounds **5** and **6** are closely related to each other, with the only difference being the presence of a hydroxymethyl function in **6** ( $\delta_{\text{H}}$  4.58, 2H, s;  $\delta_{\text{C}}$  63.3) instead of a methyl. The oxymethylene

protons showed HMBC correlations with C-6, C-7, and C-8, and NOE cross-peaks with H-6, H-13, and H-14b; therefore, it must be situated on C-7.

### 3.1.7. Ensifolin G (7)

Compound **7** was obtained as light-yellow amorphous granules. Its HRESIMS suggested the molecular formula  $C_{18}H_{18}O_3$  through the presence of a peak at  $m/z$  281.1213  $[M + H]^+$  (calcd for 281.1183). In the 1D NMR spectra, the lack of resonances of a vinyl group and the appearance of an upfield shifted methyl ( $\delta_H$  2.46, 3H, s) and a keto carbon at  $\delta_C$  211.4 demonstrated that the vinyl part of ensifolin E (**5**) was biosynthetically converted to an acetyl moiety. Its position at C-8 ( $\delta_C$  134.3) was shown by the HMBC correlations from H<sub>3</sub>-14, H-6, H<sub>3</sub>-12, and H<sub>2</sub>-9 to this particular carbon. Careful analysis of the 2D NMR spectra led to the conclusion that ensifolin G is a structural isomer of juncatrin A, a 9,10-dihydrophenanthrene previously isolated from *Juncus atratus*, in which the H-6 proton and the OH-5 group are interchanged [24].

### 3.1.8. Ensifolin H (8)

HRESIMS data provided the molecular formula of  $C_{18}H_{16}O_3$  for compound **8** through the peak of the protonated molecule at  $m/z$  281.1174 (calcd for  $C_{18}H_{17}O_3$  281.1172). Upon comparison of its 1D NMR data with those of juncatrin B, a 9,10-dihydrophenanthrene described from *J. atratus* by our research group [24], we found that the C-7 methyl group adjacent to an acetylene substituent was oxidized into a hydroxymethyl side chain. This assumption was substantiated by the HMBC correlations H<sub>2</sub>-12/C-6, H<sub>2</sub>-12/C-7, H<sub>2</sub>-12/C-8, H-5/C-7, and H-14/C-8 and by the absence of 12-methyl.

### 3.1.9. Ensifolin I (9)

The molecular formula  $C_{18}H_{14}O_2$  was assigned to compound **9** according to the HRESIMS peak of the protonated molecule at  $m/z$  263.1069  $[M + H]^+$  (calcd for 263.1067). The signals in the  $^1H$  NMR spectrum were similar to those of juncatrin B except for the replacement of its saturated H<sub>2</sub>-9/H<sub>2</sub>-10 structural part by two mutually coupled olefinic protons ( $\delta_H$  7.77 and 8.16, each 1H,  $J = 9.4$  Hz). The presence of a double bond between C-9 and C-10 was supported by the HMBC correlations recorded between H-9 ( $\delta_H$  8.16) and C-1a, C-5a, and C-8 and between H-10 ( $\delta_H$  7.77) and C-1, C-4a, and C-8a. The H-4/H-5, H<sub>3</sub>-12/H-14, H-9/H-14, and H-10/H<sub>3</sub>-11 NOE cross-peaks were in good agreement with the structure depicted in Figure 1.

### 3.1.10. Ensifolin J (10)

Compound **10** has the molecular formula  $C_{36}H_{34}O_4$  as suggested by its protonated molecule appearing at  $m/z$  531.2516  $[M + H]^+$  (calcd for 531.2530) in the HRESIMS. The 1D NMR spectra of ensifolin J were almost superimposable with those of ensifolin E (**5**) (Table 3). However, instead of *ortho*-coupled aromatic protons, it exhibited only one proton singlet in the aromatic region at  $\delta_H$  8.12, and an additional nonprotonated  $sp^2$  carbon was also seen at  $\delta_C$  124.9. These findings, in conjunction with the HRESIMS data, clearly indicated that ensifolin J is a symmetric dimeric phenanthrene comprised of two ensifolin E units. In order to confirm the connection between them, a series of 2D NMR experiments were conducted. The upfield shifted singlet of H-4 ( $\delta_H$  8.12) gave three-bond heteronuclear correlations to C-1a, C-2, C-5a, and, most importantly, to the above-mentioned carbon (C-3') resonating at  $\delta_C$  124.9. In conclusion, it was determined that the two ensifolin E monomers are linked together via their C-3 carbons resulting in a symmetrical dimer.

### 3.1.11. Ensifolin K (11)

Compound **11**, obtained as a light-yellow amorphous powder, is a phenanthrene heterodimer with the molecular formula  $C_{36}H_{32}O_4$ , as inferred by the HRESIMS peak at  $m/z$  529.2366  $[M + H]^+$  (calcd for 529.2373) and the 36 carbon resonances detected in the  $^{13}C$

JMOD NMR spectrum (Table 4). It was apparent that one of the building blocks of compound **11** is ensifolin E (**5**). The other phenanthrene monomer was identified as dehydrojuncuenin B by means of evaluation of the 2D NMR data and then by comparison of our assignments with reported literature values [29]. Taking into account that H-5 of dehydrojuncuenin B was missing, and a nonprotonated carbon at  $\delta_c$  118.6 (C-5) correlated only with the deshielded H-4' ( $\delta_H$  7.96, 1H, s) of ensifolin E, it was concluded that the monomers are connected through a C–C bond formed between C-5 of dehydrojuncuenin B and C-3' of ensifolin E (**5**).

### 3.1.12. Ensifolin L (**12**)

Compound **12** has the molecular formula  $C_{36}H_{34}O_4$ , suggested by its protonated molecular peak at  $m/z$  529.2437  $[M + H]^+$  (calcd for 529.2384) in the HRESIMS. A brief examination of the  $^1H$  NMR spectrum indicated that ensifolin L is a phenanthrene dimer composed of two ensifolin L (**5**) monomers (Table 4). Unlike ensifolin J (**10**), ensifolin L is not symmetrical, since its 1D NMR data provided two sets proton and carbon resonances ascribable to the two constructing subunits. The lack of H-6 and the presence of an upfield shifted singlet at  $\delta_H$  7.92 implied that the phenanthrene units are most likely connected by a C–C bond formed between C-6 and C-3' of the corresponding aromatic rings C and A'. This presumption was proven unequivocally by the HMBC correlations from H<sub>3</sub>-12 ( $\delta_H$  2.03, 3H, s) and H-4' ( $\delta_H$  7.92, ring A') to C-6 ( $\delta_c$  125.3, ring C) and by a diagnostic NOE cross-peak of H<sub>3</sub>-12 with H-4'.

### 3.1.13. Ensifolin M (**13**)

The molecular formula  $C_{36}H_{30}O_4$  was determined for compound **13** with the aid of an HRESIMS peak at  $m/z$  525.2118  $[M + H]^+$  (calcd for 525.2071). The  $^1H$  NMR spectrum contained a set of signals reminiscent of juncatrin B, but only two aromatic singlets were exhibited at  $\delta_H$  7.48 and 7.17 instead of three aromatic methines (the mutually coupled H-3/H-4, and H-5) that occur in the original compound (Table 3) [24]. This observation, in conjunction with the HRESIMS data, indicated ensifolin M to be a symmetrical phenanthrene dimer. The connectivity between C-3 and C-3' was unambiguously determined by the HMBC correlation of H-4 ( $\delta_H$  7.48) with a nonprotonated carbon resonating at  $\delta_c$  126.8 (C-3,3'), which displayed no heteronuclear correlations with any of the other protons. The nuclear Overhauser effects H-4/H-5 and H<sub>2</sub>-10/H<sub>3</sub>-11 were in line with the depicted structure (Figure 1).

Besides the new compounds ensifolins A–M (**1–13**), four known phenanthrenes, namely, 2-hydroxy-1,7-dimethyl-5-vinyl-9,10-dihydrophenanthrene (**14**) [30], juncuenin B (**15**) [29], juncatrin B (**16**) [24], and sylvaticin A (**17**) [27], and 4-hydroxybenzaldehyde (**18**) and luteolin (**19**) were identified from *J. ensifolius*. The structural characterization was performed by means of HRESIMS and 1D and 2D NMR experiments and then by comparison of the  $^1H$  and  $^{13}C$  assignments with reported literature data. All compounds have been isolated for the first time from this plant.

## 3.2. Antiproliferative Activity of the Compounds

The antiproliferative activity of compounds (**1–19**) was investigated in human cancer cell lines, namely, cervical cancer (HeLa), doxorubicin-sensitive colonic adenocarcinoma COLO 205, multidrug resistant colonic adenocarcinoma COLO 320/MDR-LRP expressing P-gp (MDR1)-LRP, and human embryonal lung fibroblast MRC-5. The thiazolyl blue tetrazolium bromide (MTT) assay was used for each compound to assess the concentration required for 50% inhibition of viability of the cell population ( $IC_{50}$ ) (Table 6). The luteolin-substituted phenanthrene ensifolin A (**1**) was found to be the most promising component with substantial antiproliferative effects against all three tested cell lines ( $IC_{50}$  values 3.9–12.7  $\mu M$ ) and showed good selectivity (SI = 4.95) in the case of COLO 205 cells. It was more than ten-fold as active as the positive control cisplatin in COLO 205 cells. Interestingly,

luteolin (**19**) alone and compound **7** (ensifolin G), structurally very similar to the phenanthrene unit of ensifolin A (**1**), were inactive for all tested cell lines. The lowest  $IC_{50}$  values against cervical carcinoma (HeLa) cells were found for compounds **15** ( $IC_{50} = 6.67 \pm 0.03 \mu\text{M}$ ) and **16** ( $IC_{50} = 6.65 \pm 0.10 \mu\text{M}$ ). The only difference between the two compounds is the substituent at C-8, which is a vinyl group in the case of **15**, and an acetylene group in **16**. Ensifolin E (**5**), differing from juncuenin B (**15**) only in the position of the hydroxy group (at C-5 in **5**, and at C-6 in **15**), resulted in a significant decrease in the activity against HeLa cells, while changing of the methyl group at C-7 in **5** to the hydroxymethylene group in ensifolin F (**6**) led to the loss of activity. Compounds **8** and **17** possessed moderate anti-proliferative activity ( $IC_{50}$  values  $12.31 \pm 0.13 \mu\text{M}$  and  $10.56 \pm 0.09 \mu\text{M}$ , respectively) against HeLa cells. Ensifolin I (**9**) is the dehydro derivative of sylvaticin A (**17**), and this modification resulted in an increased activity in the cases of COLO 205 and COLO 320 adenocarcinoma cell lines, while a twofold decrease in HeLa cells. Finally, dimerization of phenanthrene monomers resulted in a decrease of the activity, as it can be seen in the case of compounds **9** and **13**, while in the case of **10** and **12**, which are the dimers of ensifolin E (**5**), neither the monomer nor its dimers showed antiproliferative activity.

The best selectivity was obtained for ensifolins D (**4**,  $SI > 5.15$ , HeLa) and H (**8**,  $SI > 8.13$ , HeLa) and for compounds **15** ( $SI > 5.37$ , HeLa), **16** ( $SI > 3.91$ , HeLa), and **17** ( $SI > 9.43$ , HeLa).

**Table 6.** Antiproliferative activity ( $IC_{50}$  values) of the isolated compounds (**1–19**) ( $SI$  is the selectivity index).

Compound	$IC_{50}$ ( $\mu\text{M}$ ) $\pm$ SD				SI	SI	SI
	COLO 205	COLO 320	HeLa	MRC-5	MRC-5/COLO 205	MRC-5/COLO 320	MRC-5/HeLa
1	3.86 $\pm$ 0.08	12.71 $\pm$ 0.05	8.25 $\pm$ 0.51	19.29 $\pm$ 0.54	5.00	1.52	2.34
2	45.64 $\pm$ 0.50	37.24 $\pm$ 0.11	33.49 $\pm$ 0.29	51.87 $\pm$ 0.14	1.14	1.39	1.55
3	>100	>100	>100	>100			
4	65.61 $\pm$ 0.78	61.56 $\pm$ 9.95	19.40 $\pm$ 0.33	>100	>1.52	>1.62	>5.15
5	31.23 $\pm$ 0.66	25.17 $\pm$ 0.92	27.46 $\pm$ 1.19	44.31 $\pm$ 0.61	1.42	1.76	1.61
6	>100	93.71 $\pm$ 0.14	74.32 $\pm$ 2.98	>100		>1.07	>1.35
7	>100	>100	75.57 $\pm$ 0.94	>100			>1.32
8	>100	63.46 $\pm$ 2.70	12.31 $\pm$ 0.13	>100		>1.58	>8.12
9	18.21 $\pm$ 0.28	18.52 $\pm$ 0.06	24.09 $\pm$ 0.11	49.14 $\pm$ 0.83	2.70	2.65	2.04
10	44.48 $\pm$ 1.22	42.76 $\pm$ 1.28	33.54 $\pm$ 1.89	57.75 $\pm$ 1.32	1.30	1.35	1.72
11	31.38 $\pm$ 0.72	37.84 $\pm$ 1.05	29.53 $\pm$ 0.31	33.16 $\pm$ 0.05	1.06	0.88	1.12
12	26.91 $\pm$ 1.19	37.36 $\pm$ 2.13	30.22 $\pm$ 0.21	50.36 $\pm$ 1.30	1.87	1.35	1.67
13	42.72 $\pm$ 0.92	37.27 $\pm$ 0.55	31.51 $\pm$ 0.53	72.54 $\pm$ 1.56	1.70	1.95	2.30
14	32.92 $\pm$ 0.59	52.36 $\pm$ 0.77	58.09 $\pm$ 1.20	60.89 $\pm$ 0.25	1.85	1.16	1.05
15	37.08 $\pm$ 0.57	30.54 $\pm$ 0.93	6.67 $\pm$ 0.03	35.85 $\pm$ 1.23	0.97	1.17	5.37
16	34.42 $\pm$ 0.57	32.48 $\pm$ 0.75	6.65 $\pm$ 0.10	26.03 $\pm$ 0.85	0.76	0.80	3.91
17	56.73 $\pm$ 0.75	57.66 $\pm$ 0.92	10.56 $\pm$ 0.09	>100	>1.76	>1.73	>9.47
18	>100	>100	>100	>100			
19	>100	>100	>100	>100			
DMSO	>1%	>1%	>1%	>1%			
cisplatin	41.67 $\pm$ 1.62	2.14 $\pm$ 0.32	3.62 $\pm$ 0.16	2.36 $\pm$ 0.33			
doxorubicin	1.36 $\pm$ 0.36	0.22 $\pm$ 0.004	0.04 $\pm$ 0.004	0.53 $\pm$ 0.06			

Four parallel measurements were applied for all tested compounds.  $SI$ : selectivity index; The selectivity indexes ( $SI$ ) were calculated as the ratio of the  $IC_{50}$  value in the non-tumour cells and the  $IC_{50}$  in the cancer cell lines. The compound's activity towards cancer cells is considered strongly selective if the selectivity index ( $SI$ ) value is higher than 6, moderately selective if  $3 < SI < 6$ , slightly selective if  $1 < SI < 3$ , and non-selective if  $SI$  is lower than 1.



### 3.3. Drug Combination Assay

Many types of cancers are highly resistant to the currently available chemotherapeutic agents. Therefore, new effective and well-tolerated therapy strategies are needed. One of the possibilities is the identification of new bioactive natural products. Therefore, a chemosensitivity assay was carried out by studying the *in vitro* interactions between the compounds and the antineoplastic drug doxorubicin, known to be transported by P-gp. Therefore, a combination chemotherapy model on human HeLa cervical carcinoma cells was performed. The combination index (CI), based on the Chou and Talalay method, was the main parameter to assess drug–drug interactions as synergistic (CI < 1), additive (CI = 1) or antagonistic (CI > 1) (Table 7) [22].

**Table 7.** Interaction type between doxorubicin and phenanthrenes (1–17) in HeLa cells.

Compound	CI	SD	Ratio	Interaction
1	0.272	0.2124	9.28:1	strong synergism
2	0.584	0.0510	23.2:1	synergism
3	0.580	0.0387	13.92:1	synergism
4	0.643	0.1623	55.68:1	synergism
5	0.001	0.0003	9.28:1	very strong synergism
6	0.159	0.1414	23.2:1	strong synergism
7	0.568	0.0268	46.4:1	synergism
8	0.033	0.0106	185.6:1	very strong synergism
9	0.180	0.0675	9.28:1	strong synergism
10	0.454	0.0269	38.4:1	synergism
11	0.112	0.0387	10.44:1	strong synergism
12	0.120	0.0418	11.6:1	strong synergism
13	0.445	0.1202	46.4:1	synergism
14	0.579	0.0855	92.8:1	synergism
15	0.864	0.2338	27.84:1	slight synergism
16	0.682	0.3743	13.92:1	synergism
17	0.279	0.0574	13.92:1	strong synergism

Combination index (CI) values are expressed as the average of CI values calculated based on different drug ratios  $\pm$  standard deviation (SD) for an inhibitory concentration of 50% (IC<sub>50</sub>). CI < 0.1: very strong synergism; 0.1 < CI < 0.3: strong synergism; 0.3 < CI < 0.7: synergism; 0.7 < CI < 0.9: moderate to slight synergism; 0.9 < CI < 1.1: nearly additive; 1.1 < CI < 1.45: slight to moderate antagonism; 1.45 < CI < 3.30: antagonism [31].

As can be observed in Table 6, all derivatives tested were found to interact synergistically with doxorubicin (CI < 1) in the HeLa cell line. Very strong synergisms were observed for ensifolins E (5) and H (8), with CI values lower than 0.1. Both compounds showed weak or moderate activity (IC<sub>50</sub>s 25.2–31.2  $\mu$ M for 5, and 12.3–63.5  $\mu$ M for 8) in the case of antiproliferative investigation.

## 4. Conclusions

In this investigation, 17 phenanthrenes, among them ensifolins A–M (1–13) as new natural products, four known ones (14–17), and 4-hydroxybenzaldehyde (18) and luteolin (19), were characterized from the whole plant of *J. ensifolius*. Their planar structures were elucidated by comprehensive spectroscopic data. All compounds were determined for the first time from the plant. Compounds 1 and 15–17 displayed *in vitro* antiproliferative activity against different tumor cell lines. The luteolin-substituted phenanthrene (1) was found to be the most promising component with substantial antiproliferative effects against COLO 205 cells (IC<sub>50</sub> value 3.9  $\mu$ M). Moreover, compounds 5 and 8 possessed very strong synergism with doxorubicin in the drug combination assay. These findings not

only enrich the chemical diversity of phenanthrenes but also provide new natural small molecules for further antiproliferative investigations.

**Supplementary Materials:** The following supporting information can be downloaded at: [www.mdpi.com/article/10.3390/pharmaceutics14030608/s1](http://www.mdpi.com/article/10.3390/pharmaceutics14030608/s1), Figures S1–S78: NMR spectra of isolated compounds (1–13).

**Author Contributions:** Conceptualization, A.V. and G.S.; methodology, A.V. and G.S.; software, D.S. and N.S.; investigation, D.S., N.K., N.S., A.B., and R.B.; resources, A.V.; writing—original draft preparation, D.S., N.K. and A.V.; writing—review and editing, A.V. and J.H.; project administration, A.V.; funding acquisition, A.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Economic Development and Innovation Operative Program GINOP-2.3.2-15-2016-00012, the UNKP-20-3-II New National Excellence Program of the Ministry of Human Capacities, EFOP-3.6.3-VEKOP-16-2017-00009, and the National Research, Development and Innovation Office, Hungary (NKFIH; K128963).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## References

1. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J. Nat. Prod.* **2020**, *83*, 770–803.
2. Juaid, N.; Amin, A.; Abdalla, A.; Reese, K.; Alamri, Z.; Moulay, M.; Abdu, S.; Miled, N. Anti-hepatocellular carcinoma biomolecules: Molecular targets insights. *Int. J. Mol. Sci.* **2021**, *22*, 10774.
3. Abdalla, A.; Murali, C.; Amin, A. Safranal inhibits angiogenesis via targeting HIF-1 $\alpha$ /VEGF machinery: In vitro and ex vivo insights. *Front. Oncol.* **2022**, *11*, 789172.
4. Hamza, A.A.; Heeba, G.H.; Hamza, S.; Abdalla, A.; Amin, A. Standardized extract of ginger ameliorates liver cancer by reducing proliferation and inducing apoptosis through inhibition oxidative stress/inflammation pathway. *Biomed. Pharmacother.* **2021**, *134*, 111102.
5. Kojima-Yuasa, A.; Huang, X.; Matsui-Yuasa, I. Synergistic anticancer activities of natural substances in human hepatocellular carcinoma. *Diseases* **2015**, *3*, 260–281.
6. Cao, H.; Phan, H.; Yang, I.X. Improved chemotherapy for hepatocellular carcinoma. *Anticancer Res.* **2012**, *32*, 1379–1386.
7. Lagoa, R.; Silva, J.; Rodrigues, J.R.; Bishayee, A. Advances in phytochemical delivery systems for improved anticancer activity. *Biotechnol. Adv.* **2020**, *38*, 107382.
8. Baig, B.; Halim, S.A.; Farrukh, A.; Greish, Y.; Amin, A. Current status of nanomaterial-based treatment for hepatocellular carcinoma. *Biomed. Pharmacother.* **2019**, *116*, 108852.
9. Vasas, A. Phenanthrenes from Orchidaceae and Their Biological Activities. In *Orchids Phytochemistry, Biology and Horticulture*; Merillon, J.M., Kodja, H., Eds.; Reference Series in Phytochemistry; Springer: Cham, Switzerland, 2021; pp. 1–41. [https://doi.org/10.1007/978-3-030-11257-8\\_34-1](https://doi.org/10.1007/978-3-030-11257-8_34-1).
10. Bús, C.; Tóth, B.; Stefkó, D.; Hohmann, J.; Vasas, A. Family Juncaceae: Promising source of biologically active natural phenanthrenes. *Phytochem. Rev.* **2018**, *17*, 833–851. <https://doi.org/10.1007/s11101-018-9561-5>.
11. Tóth, B.; Hohmann, J.; Vasas, A. Phenanthrenes: A promising group of plant secondary metabolites. *J. Nat. Prod.* **2018**, *81*, 661–678.
12. Liu, W.; Meng, M.; Zhang, B.; Du, L.; Pan, Y.; Yang, P.; Gu, Z.; Zhou, Q.; Cao, Z. Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity. *Toxicol. Appl. Pharmacol.* **2015**, *287*, 98–110.
13. Zhang, B.; Han, H.; Fu, S.; Yang, P.; Gu, Z.; Zhou, Q.; Cao, Z. Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis. *Biochem. Pharmacol.* **2016**, *104*, 8–18.
14. Kuo, C.Y.; Schelz, Zs.; Tóth, B.; Vasas, A.; Ocsovszki, I.; Chang, F.R.; Hohmann, J.; Zupkó, I.; Wang, H.C. Investigation of natural phenanthrenes and the antiproliferative potential of juncusol in cervical cancer cell lines. *Phytomedicine* **2019**, *58*, 152770.
15. Bús, C.; Kulmány, Á.; Kúsz, N.; Gonda, T.; Zupkó, I.; Mándi, A.; Kurtán, T.; Tóth, B.; Hohmann, J.; Hunyadi, A.; Vasas, A. Oxidized juncuenin B analogues with increased antiproliferative activity on human adherent cell lines: Semisynthesis and biological evaluation. *J. Nat. Prod.* **2020**, *83*, 3250–3261.

16. Tóth, B.; Chang, F.R.; Hwang, T.L.; Szappanos, Á.; Mándi, A.; Hunyadi, A.; Kurtán, T.; Jakab, G.; Hohmann, J.; Vasas, A. Screening of *Luzula* species native to the Carpathian Basin for anti-inflammatory activity and bioactivity-guided isolation of compounds from *Luzula luzuloides* (Lam.) Dandy & Wilmott. *Fitoterapia* **2017**, *116*, 131–138.
17. *Juncus ensifolius*. Invasive Species Compendium. Available online: <https://www.cabi.org/isc/datasheet/115030#147582B0-EA1E-4137-A35A-F2A22FA1DBF2> (accessed on 9 January 2022).
18. Reagan, A.B. Plants used by the Hoh and Quileute Indians. *Trans. Kans. Acad. Sci.* **1936**, *37*, 55–70.
19. Gunther, E. *Ethnobotany of Western Washington (Revised Edition)*; University of Washington Press: Seattle, WA, USA, 1973.
20. Bacher, F.; Wittmann, C.; Nové, M.; Spengler, G.; Marć, M.A.; Enyedy, E.A.; Darvasiová, D.; Rapta, P.; Reinere, T.; Arion, V.B. Novel latonduine derived proligands and their copper(II) complexes show cytotoxicity in the nanomolar range in human colon adenocarcinoma cells and in vitro cancer selectivity. *Dalton Trans.* **2019**, *48*, 10464.
21. *CompuSyn*, version 1.00; ComboSyn, Inc.: Paramus, NJ, USA, 2005.
22. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* **2006**, *58*, 621–681. <https://doi.org/10.1124/pr.58.3.10>.
23. Chou, T.C. Drug Combination Studies and their Synergy Quantification Using the Chou-Talalay Method. *Cancer Res.* **2010**, *70*, 440–446. <https://doi.org/10.1158/0008-5472.CAN-09-1947>.
24. Stefkó, D.; Kúsz, N.; Csorba, A.; Jakab, G.; Bérdi, P.; Zupkó, I.; Hohmann, J.; Vasas, A. Phenanthrenes from *Juncus atratus* with antiproliferative activity. *Tetrahedron* **2019**, *75*, 116–120.
25. Bús, C.; Kúsz, N.; Jakab, G.; Senobar Tahaei, S.A.; Zupkó, I.; Endrész, V.; Bogdanov, A.; Burián, K.; Csupor-Löffler, B.; Hohmann, J.; et al. Phenanthrenes from *Juncus compressus* Jacq. with promising antiproliferative and anti-HSV-2 activities. *Molecules* **2018**, *23*, 2085. <https://doi.org/10.3390/molecules23082085>.
26. Lin, L.C.; Pai, Y.F.; Tsai, T.H. Isolation of luteolin and luteolin-7-O-glucoside from *Dendranthema morifolium* Ramat Tzvel and their pharmacokinetics in rats. *J. Agric. Food Chem.* **2015**, *63*, 7700–7706.
27. Gainche, M.; Ripoche, I.; Senejoux, F.; Cholet, J.; Ogeron, C.; Decombat, C.; Danton, O.; Delort, L.; Varelle-Delarbre, M.; Berry, A.; et al. Anti-inflammatory and cytotoxic potential of new phenanthrenoids from *Luzula sylvatica*. *Molecules* **2020**, *25*, 2372.
28. Resnick, S.M.; Gibson, D.T. Regio- and stereospecific oxidation of 9,10-dihydroanthracene and 9,10-dihydrophenanthrene by naphthalene dioxygenase: Structure and absolute stereochemistry of metabolites. *Appl. Environ. Microbiol.* **1996**, *62*, 3355–3359.
29. Wang, X.Y.; Ke, C.Q.; Tang, C.P.; Yuan, D.; Ye, Y. 9,10-Dihydrophenanthrenes and phenanthrenes from *Juncus setchuensis*. *J. Nat. Prod.* **2009**, *72*, 1209–1212. <https://doi.org/10.1021/np9000834>.
30. Della Greca, M.; Fiorentino, A.; Monaco, P.; Pinto, G.; Pollio, A.; Previtera, L. Action of antialgal compounds from *Juncus effusus* L. on *Selenastrum capricornutum*. *J. Chem. Ecol.* **1996**, *22*, 587–603.
31. Ferreira, M.J.U.; Duarte, N.; Reis, M.; Madureira, A.M.; Molnar, J. *Euphorbia* and *Momordica* metabolites for overcoming multi-drug resistance. *Phytochem. Rev.* **2014**, *13*, 915–935. <https://doi.org/10.1007/s11101-014-9342-8>.